Skip to NavigationSkip to content

Summary of Hypertrophic Cardiomyopathy - ref #BS000005

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Hypertrophic cardiomyopathy in 8 Major Markets

Hypertrophic cardiomyopathy (HCM) is a disease that contains an autosomal dominant inheritance pattern and is a moderately common “transmitted” genetic disease. The disease, characterized by hypertrophy in the left ventricle, cannot be explained by the presence of other clinical symptoms, such as hypertension. This report provides the current prevalent population for HCM across 8 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil and Japan) split by gender and 5-year age cohort. Along with the current prevalence, the report provides an overview of the types, occlusion locations and the prevalence of associated disorders of HCM. The report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of HCM have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for HCM include:

  • Chronic heart failure
  • Angina pectoris
  • Atrial fibrillation
  • Tachycardia

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

  • Able to quantify patient populations in global HCM’s market to target the development of future products, pricing strategies and launch plans.
  • Gain further insight into the prevalence of the subdivided types of HCM and identify patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Provide a level of understanding on the impact from specific co-morbid conditions on HCM’s prevalent population.
  • Examination of the prevalence of the different causative gene mutations for HCM.
  • Identify sub-populations within HCM which require treatment.
  • Gain an understanding of the specific markets that have the largest number of HCM patients. 

The content of this report includes:

  • List of Tables & Figures
  • Overview
  • Introduction
  • Cause of the Disease
  • Risk Factors & Prevention
  • Diagnosis of the Disease
  • Variation by Geography/Ethnicity
  • Disease Prognosis &Clinical Course
  • Key Co-morbid Conditions/Features Associated with the Disease
  • Methodology for Quantification of Patient Numbers
  • Top-Line Prevalence for Hypertrophic Cardiomyopathy
  • Main Type and Cardiac Features of Hypertrophic Cardiomyopathy
    • HCM main type
    • HCM by symptoms 
    • Cardiac features of HCM 
    • HCM related death
  • Significant Co-morbid Conditions Associated with HCM
  • Gene Mutations within HCM
  • References
  • Appendix

Tables and figures within this report include:

  1. Prevalence of HCM, total (000s)
  2. Prevalence of HCM, males (000s)
  3. Prevalence of HCM, females (000s)
  4. HCM by main type – familial vs. sporadic, total (000s)
  5. Symptomatic HCM, total (000s)
  6. Dyspnoea within symptomatic HCM (000s)
  7. Clinical heart failure within symptomatic HCM (000s)
  8. Angina pectoris within symptomatic HCM (000s)
  9. Syncope within symptomatic HCM (000s)
  10. Paroxysmal supraventricular tachycardia within symptomatic HCM (000s)
  11. Dynamic Left Ventricular Outflow obstruction (LVOT) in patients with HCM, total (000s)
  12. Maximum Left Ventricular Thickness (LVT) in patients with HCM, total (000s)
  13. Causes of death associated with HCM, total (000s)
  14. Prevalence of hypertension in patients with HCM, total (000s)
  15. Prevalence of atrial fibrillation in patients with HCM, total (000s)
  16. Key gene mutation within HCM patients, total (000s)
  17. USA Prevalence of HCM by 5-yr age cohort, males (000s)
  18. USA Prevalence of HCM by 5-yr age cohort, females (000s)
  19. France Prevalence of HCM by 5-yr age cohort, males (000s)
  20. France Prevalence of HCM by 5-yr age cohort, females (000s)
  21. Germany Prevalence of HCM by 5-yr age cohort, males (000s)
  22. Germany Prevalence of HCM by 5-yr age cohort, females (000s)
  23. Italy Prevalence of HCM by 5-yr age cohort, males (000s)
  24. Italy Prevalence of HCM by 5-yr age cohort, females (000s)
  25. Spain Prevalence of HCM by 5-yr age cohort, males (000s)
  26. Spain Prevalence of HCM by 5-yr age cohort, females (000s)
  27. United Kingdom Prevalence of HCM by 5-yr age cohort, males (000s)
  28. United Kingdom Prevalence of HCM by 5-yr age cohort, females (000s)
  29. Brazil Prevalence of HCM by 5-yr age cohort, males (000s)
  30. Brazil Prevalence of HCM by 5-yr age cohort, females (000s)
  31. Japan Prevalence of HCM by 5-yr age cohort, males (000s)
  32. Japan Prevalence of HCM by 5-yr age cohort, females (000s)

Publisher: Black Swan
Date published: August 2015

Price: £ 3,950.00

You need to agree to the Terms and Conditions before placing your order

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches